Empliciti (elotuzumab) vs Sarclisa (isatuximab)
Empliciti (elotuzumab) vs Sarclisa (isatuximab)
Empliciti (elotuzumab) and Sarclisa (isatuximab) are both monoclonal antibodies used in the treatment of multiple myeloma, but they target different proteins on the surface of cancer cells. Empliciti binds to the SLAMF7 protein, enhancing the immune system's ability to kill myeloma cells, and is typically used in combination with other medications like lenalidomide and dexamethasone. Sarclisa targets the CD38 protein and can be used in combination with pomalidomide and dexamethasone or with carfilzomib and dexamethasone; it is known for its direct and indirect mechanisms of action against myeloma cells, including immune system engagement and interference with the cell's metabolism. The choice between the two would depend on the individual's specific medical condition, prior treatments, and potential side effects, and should be made in consultation with a healthcare provider.
Difference between Empliciti and Sarclisa
Metric | Empliciti (elotuzumab) | Sarclisa (isatuximab) |
---|---|---|
Generic name | Elotuzumab | Isatuximab |
Indications | Multiple myeloma (in combination with lenalidomide and dexamethasone) | Multiple myeloma (in combination with pomalidomide and dexamethasone, or carfilzomib and dexamethasone) |
Mechanism of action | SLAMF7-directed immunostimulatory antibody | CD38-directed cytolytic antibody |
Brand names | Empliciti | Sarclisa |
Administrative route | Intravenous infusion | Intravenous infusion |
Side effects | Fatigue, diarrhea, fever, constipation, cough, peripheral neuropathy, nasopharyngitis, upper respiratory tract infection, decreased appetite, pneumonia | Neutropenia, infusion-related reactions, pneumonia, upper respiratory tract infection, diarrhea |
Contraindications | Hypersensitivity to elotuzumab or excipients | Hypersensitivity to isatuximab or excipients |
Drug class | Monoclonal antibody | Monoclonal antibody |
Manufacturer | Bristol-Myers Squibb | Sanofi |
Efficacy
Empliciti (Elotuzumab) Efficacy in Multiple Myeloma
Empliciti, also known by its generic name elotuzumab, is a monoclonal antibody used in the treatment of multiple myeloma, a type of blood cancer that affects plasma cells. It is specifically indicated for use in combination with other medications, such as lenalidomide and dexamethasone, for the treatment of patients who have received one to three prior therapies. Clinical trials have demonstrated that Empliciti, when added to lenalidomide and dexamethasone, can significantly extend progression-free survival compared to lenalidomide and dexamethasone alone. This suggests that Empliciti can be an effective part of a combination regimen for relapsed or refractory multiple myeloma patients.
Sarclisa (Isatuximab) Efficacy in Multiple Myeloma
Sarclisa, with the generic name isatuximab, is another monoclonal antibody that targets the CD38 molecule on the surface of multiple myeloma cells. It is approved for use in combination with pomalidomide and dexamethasone for the treatment of adult patients with multiple myeloma who have received at least two prior therapies including lenalidomide and a proteasome inhibitor. In clinical studies, Sarclisa has shown to provide a significant improvement in progression-free survival when compared to pomalidomide and dexamethasone alone. This indicates that Sarclisa is effective for patients with relapsed and refractory multiple myeloma, particularly after other treatments have failed.
Comparative Efficacy
While both Empliciti and Sarclisa are used to treat multiple myeloma, they are typically used in different combinations and at different stages of the disease. Direct comparisons in clinical efficacy between Empliciti and Sarclisa are not widely available as they have been studied in different patient populations and with different combination therapies. However, both have shown to be beneficial additions to multiple myeloma treatment regimens, improving outcomes for patients who have previously undergone therapy.
Conclusion
In conclusion, Empliciti (elotuzumab) and Sarclisa (isatuximab) have both demonstrated efficacy in improving patient outcomes in multiple myeloma, particularly in the relapsed or refractory setting. Their use in combination with other agents is a reflection of the evolving and complex treatment landscape of multiple myeloma, where combination therapy is becoming the standard of care. The choice between Empliciti and Sarclisa as a treatment option would depend on the individual patient's treatment history, the specific combination regimen being considered, and the clinical judgment of the healthcare provider.
Regulatory Agency Approvals
Empliciti
Sarclisa
Access Empliciti or Sarclisa today
If Empliciti or Sarclisa are not approved or available in your country (e.g. due to supply issues), you can access them via Everyone.org.
How it works
Make an enquiry
Choose the medicine you want to buy, answer a couple of questions, and upload your prescription to speed things up. We’ll get back to you within 24 hours.
Make an enquiry
Choose the medicine you want to buy, answer a couple of questions, and upload your prescription to speed things up. We’ll get back to you within 24 hours.
Breeze through the paperwork
We'll guide you through the required documents for importing unapproved medicine, ensuring you have all the necessary information.
Get a personalized quote
We’ll prepare a quote for you, including medicine costs and any shipping, administrative, or import fees that may apply.
Receive your medicine
Accept the quote and we’ll handle the rest - sourcing and safely delivering your medicine.
Some text on this page has been automatically generated. Speak to your physician before you start a new treatment or medication.
Let's talk
If you have any questions, call us or send us a message through WhatsApp or email:
Contact us